Bupropion — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Major Depressive Disorder

• Citalopram
• Duloxetine
• Escitalopram
• Fluoxetine
• Mirtazapine
• Paroxetine
• Sertraline
• Trazodone

Other medications in Mental Health

• Buspirone
• Cariprazine
• Chlordiazepoxide
• Chlorpromazine
• Clomipramine
• Clonazepam
• Clonidine
• Clorazepate

What Bupropion is approved for (FDA label)

Bupropion hydrochloride extended-release tablets, USP (XL) is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient. ( 1 ) 1.1 Major Depressive Disorder Bupropion hydrochloride extended-release tablets, USP (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).

Source: Read the full FDA label on DailyMed. Label effective date: January 1, 2021.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Bupropion (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) • Serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation. ( 5.2 ) WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; NEUROPSYCHIATRIC REACTIONS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressants use in subjects aged 65 and older [see Warnings and Precautions ( 5.1 ) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions ( 5.1 ) ]. NEUROPSYCHIATRIC REACTIONS IN PATIENTS TAKING BUPROPION FOR SMOKING CESSATION Serious neuropsychiatric reactions have occurred in patients taking bupropion for smoking cessation [see Warnings and Precautions ( 5.2 ) ]. The majority of these reactions occurred during bupropion treatment, but some occurred in the context of discontinuing treatment.

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Bupropion (FDA label)

• Extended-release tablets: 300 mg ( 3 ) Bupropion Hydrochloride Extended-release Tablets USP (XL), 300 mg are creamy-white to pale-yellow, round, biconvex, coated-tablets imprinted with '354' in black ink on one side and plain on other side.

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Bupropion (FDA label)

Most common adverse reactions are (incidence ≥ 5%; ≥ 2 placebo rate): dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Bupropion (FDA label)

• Seizure disorder. ( 4 , 5.3 ) • Current or prior diagnosis of bulimia or anorexia nervosa ( 4 , 5.3 ) • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. ( 4 , 5.3 ) • Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with bupropion hydrochloride extended-release tablets (XL) or within 14 days of stopping treatment with bupropion hydrochloride extended-release tablets (XL). Do not use bupropion hydrochloride extended-release tablets (XL) within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start bupropion hydrochloride extended-release tablets (XL) in a patient who is being treated with linezolid or intravenous methylene blue. ( 4 , 7.6 ) • Known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL) ( 4 , 5.8 ) • Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Bupropion (FDA label)

• Seizure risk: The risk is dose-related. Can minimize risk by limiting daily dose to 450 mg and gradually increasing the dose. Discontinue if seizure occurs. ( 4 , 5.3 , 7.3 ) • Hypertension: Bupropion hydrochloride extended-release tablets (XL) can increase blood pressure.

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Bupropion (FDA label)

• CYP2B6 inducers: Dose increase may be necessary if coadministered with CYP2B6 inducers (e.g., ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) based on clinical exposure, but should not exceed the maximum recommended dose. ( 7.1 ) • Drugs metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).

Source: FDA prescribing information (DailyMed). Set ID: 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8. SPL document ID: 001c902a-af30-40fb-bb22-cc18bd8fc94c. Label effective date: January 1, 2021. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.